Suvorexant Inversely Affects Phosphorylated Tau in Human Cerebrospinal Fluid and Plasma

Alzheimer disease (AD) is characterized by amyloid-{beta} plaques and neurofibrillary tangles of tau. Suvorexant, a dual orexin receptor antagonist, was previously shown to acutely reduce the ratio of phosphorylated tau-181 to unphosphorylated tau-181 (pT181/T181) in cerebrospinal fluid (CSF). However, its effects on plasma pT181/T181 and broader proteomic networks remain unknown. Here, we conducted a secondary analysis of samples from a randomized, placebo-controlled trial of 25 participants receiving placebo or suvorexant 20 mg. Paired CSF and plasma samples were collected longitudinally via

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.